comparemela.com

Latest Breaking News On - Galectin therapeutic - Page 1 : comparemela.com

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

29.03.2024 - NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended .

Richard uihleinChris calabreseJack callicuttKhurram jamilKevin gardnerBenjamins carsonPol boudesCompany annual report on formBelapectin programDrug administrationCompany contactExchange commissionGalectin therapeutics incChief medical officerFast track designationData safety

Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K -March 29, 2024 at 07:59 am EDT

Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31,.

Khurram jamilChris calabreseBenjamins carsonJack callicuttJoel lewisPol boudesRichard uihleinKevin gardnerCompany annual report on formExchange commissionCompany contactBelapectin programDrug administrationGalectin therapeutics incGalectin therapeutics reportsProvides business update

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M D as Vice President, Clinical Development

NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target .

United statesPolf boudesChris calabreseKhurram jamilJack callicuttKevin gardnerCompany annual report on formGalectin therapeutics incKing edward medical university at lahoreOrganon pharmaceuticals united statesClinical developmentMallinckrodt pharmaceuticalsIkaria incSeaton hall universityCompany contactDrug administration

Retail investors account for 55% of Galectin Therapeutics Inc s (NASDAQ:GALT) ownership, while insiders account for 21%

Key Insights Galectin Therapeutics' significant retail investors ownership suggests that the key decisions are.

Joel lewisRichard uihleinGalectin therapeutics incGalectin therapeuticGalectin therapeuticsGalectin therapeutics incRetail investors

Reviewing Xilio Therapeutics (NASDAQ:XLO) & Galectin Therapeutics (NASDAQ:GALT)

Reviewing Xilio Therapeutics (NASDAQ:XLO) & Galectin Therapeutics (NASDAQ:GALT)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesXilio therapeutics incGalectin sciencesSciences incPharmaceuticals incGalectin therapeutics incXilio therapeuticsGet free reportGalectin therapeuticsGiven xilio therapeuticGalectin therapeuticTherapeutics incXilio therapeutics daily

vimarsana © 2020. All Rights Reserved.